Sanofi Archives

News and Trends 23 Dec 2016

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […]

December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 16 at 4.59.08 PM e1481904006793

News and Trends 19 Dec 2016

How is Biotech responding to Patient Advocacy in Rare Disease?

A panel of experts in rare disease discussed some of the latest trends at Labiotech Refresh, focusing on the growing patient involvement and how it is benefiting this field. Rare diseases are attracting biotech and pharma more and more since they are typically less crowded areas with unmet clinical needs. However, the lower numbers of […]

December 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Dec 2016

Sanofi Jumps into the Biosimilars Market aiming for Asia

Sanofi is joining the biosimilars trend to challenge Roche’s best-selling biological with a partnership that aims to take over the Chinese cancer market. Sanofi is going after the €6.8B ($7.3B) that Roche’s Rituxan/MabThera (rituximab), the second top-selling biological, made last year in revenues. The French pharma has signed a deal worth up to €219M ($236M) […]

December 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

UPDATE: The HIV Frontier starts Phase III Vaccine trials in South Africa

Update (01/12/2016): The HVTN 702 trial has been started, making it the first HIV vaccine efficacy study in 7 years worldwide. Results are expected in late 2020. Originally published 25/07/2016 A Phase IIb/III trial for an experimental HIV vaccine just started in South Africa. The therapy, co-funded by the NIH and the Gates Foundation, is a combination […]

December 1, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 22 Nov 2016

Sanofi quietly leaves Bladder Cancer Patients in the lurch

Sanofi is halting the production of the main bladder cancer drug. In response, doctors are pressuring regulatory agencies to take action against this instance of a widespread issue of drug shortages. Sanofi Pasteur announced last week that it will be shutting down the production of the cancer drug BCG (TheraCys and ImmuCyst) in mid-2017. This drug […]

November 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy for hemophilia. But is RNAi really such a good investment? Sanofi Genzyme signed a deal with Alnylam back in 2014 to develop RNAi therapies. Now, despite the general discouragement in RNAi technology, Sanofi has decided to go ahead and […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Nov 2016

Results from 45% of Clinical Trials are kept Secret

A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported. TrialsTracker is a tool developed at the University of Oxford that automatically rates transparency on clinical trials by checking if there are results available in clinicaltrials.gov and PubMed. The results: globally, 45% of data on […]

November 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Sep 2016

Sanofi & Google Joint Venture could Revolutionize Diabetes

Sanofi and Verily, formerly Google Life Sciences, have signed a deal to form a €444M joint venture, Onduo. Its aim is to integrate medicine and microelectronics to tackle diabetes. Steve Jobs prophesied that “the biggest innovations of the twenty-first century will be the intersection of biology and technology,” and it appears that Verily, a division of […]

September 12, 2016 - 3 minutesmins - By Evelyn Warner

sanofi novo nordisk diabetes insulin glp 1 agonist combination

News and Trends 22 Aug 2016

Sanofi loses lead on new Diabetes drug, because of… an user-unfriendly Pen

Sanofi and Novo Nordisk have been in a tight race to put their new insulin GLP-1 combination drugs for Type 2 Diabetes on the market. Sanofi now suffers a short (but critical) setback, as the FDA is not impressed with its drug delivery system. Sanofi and Novo Nordisk have both strong positions in the diabetes […]

August 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

sanofi biotech acquisition medivation msd

News and Trends 22 Aug 2016

UPDATE: Sanofi defeated in the Race to acquire Medivation

Even more Big Pharma join the fight to acquire the extremely desirable Medivation, a Biotech developing cancer treatments. Now MSD is joining the bandwagon. Things don’t look so good for Sanofi, which already got rebuffed twice. UPDATE (article originally published on 18/8/2016): Pfizer has struck a deal to acquire Medivation for $14Bn (€12.4Bn), according to the Financial Times. This was […]

August 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

sanofi genzyme antibodies geel pompe leukemia

News and Trends 29 Apr 2016

Big Pharma invest massively in Biomanufacturing facilities

Sanofi is pumping €300M into its current manufacturing site in Belgium. This will support its antibody pipeline, with new laboratories of quality control and manufacturing sciences. Sanofi, France’s largest Pharma, seems to be betting more and more in biologics. Just a few years after buying Genzyme, it’s giving its subsidiary more prominence in their R&D. Now, […]

April 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

genzyme sanofi enzyme replacement therapy pompe disease neogaa neo1

News and Trends 8 Mar 2016

Sanofi Genzyme goes to Phase III with Rare Neuromuscular Disease

Sanofi Genzyme (Boston and France) have obtained good phase I/II results with a candidate for the rare Pompe Disease and expects to move to phase III in the second quarter of 2016. Sanofi Genzyme continues to bet on rare diseases and neurodegenerative disorders, now with a therapy for late-onset Pompe Disease. Pompe Disease is a […]

March 8, 2016 - 2 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us